newsfilter
← Latest News
GlobeNewswire·

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

  • Altimmune, Inc. (NASDAQ: ALT) will report its third quarter 2026 financial results on Thursday, November 12, 2026.
  • Management will host a conference call at 8:30 a.m. ET on November 12 to discuss financial results & provide a business update.
  • The conference call will be webcast live on Altimmune's Investor Relations website, with dial-in registration & a replay available for up to three months.
  • Pemvidutide is an investigational balanced 1:1 glucagon/GLP-1 receptor agonist currently in late-stage clinical development for metabolic dysfunction-associated steatohepatitis (MASH).
  • Pemvidutide recently showed robust results in the RECLAIM Phase 2 trial for alcohol use disorder (AUD) & is being studied for alcohol-associated liver disease (ALD).